Pharmacokinetics of anti-thymocyte globulin in a patient with severe aplastic anemia treated with allogeneic bone marrow transplantation from a matched unrelated donor

Noriaki Kawano1, Kana Matsumoto2, Akiyoshi Takami2, Taro Tochigi2, Shuro Yoshida1, Takuro Kuriyama1, Takashi Nakaike1, Tomonori Shimokawa1, Kiyoshi Yamashita1, Koichi Mashiba1, Ikuo Kikuchi1, Shinji Nakao4

1Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan, 2Department of Clinical Pharmaceutics, Faculty of Pharmaceutical Sciences, Doshisha Women’s College of Liberal Arts, Kyotanabe, Japan, 3Division of Hematology, Department of Internal Medicine, Aichi Medical University School of Medicine, Yazakokarimata, Nagakute, Japan, 4Department of Hematology, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan

Abstract

Anti-thymocyte globulin (ATG) is an important component of preparative regimens for allogeneic bone marrow transplantation (BMT) for aplastic anemia (AA). However, the pharmacokinetics (PK) of ATG are unclear. A 38-year-old woman with severe AA underwent BMT using a fludarabine (Flu)-based and reduced-dose cyclophosphamide (CPA)-conditioning regimen comprising rabbit ATG (2.5 mg/kg, days −7 and −6), Flu (30 mg/sqm, days −5 to −2), CPA (25 mg/kg, days −5 to −2), and total body irradiation (2 Gy, day −1), following a human leukocyte antigen-match with an unrelated donor. Notably, ATG was administered earlier than that recommended by conventional schedules. The engraftment was achieved on day 15 without reactivation of the Epstein-Barr virus and residual recipient cells. Absolute lymphocyte recovery (>0.5 × 10^9/L) was achieved on day 22. The ATG concentration on day 0 and the area under the concentration-time curve (AUC) for ATG after allogeneic BMT were 21.8 μg/mL and 464 μg·day/mL, respectively. The patient remained disease-free for 6 years after BMT without acute or chronic graft-versus-host disease. Moreover, based on serum PK monitoring of ATG, including ATG concentration on day 0 and the AUC for ATG after BMT, the patient safely underwent the less-toxic, Flu-based, reduced-dose CPA regimen containing a low dose of ATG. In conclusion, we present the first report that analyzed the PK of ATG in a patient with AA treated with BMT from a matched unrelated donor. These findings might be helpful to determine ATG dosages for such patients receiving similar transplantations.

Key words: aplastic anemia, pharmacokinetics, anti-thymocyte globulin, reduced conditioning, total body irradiation

Submitted August 4, 2020; Accepted October 26, 2020; Published online December 28, 2020; Issued online February 25, 2021

Correspondence: Noriaki Kawano, Department of Internal medicine, Miyazaki Prefectural Miyazaki Hospital, 5-30, Kita-takamatsu, Miyazaki, Japan, 880-8510, E-mail: kawanoriaki@yahoo.co.jp

Introduction

Novel treatments, including immunosuppressive therapy (IST) and allogeneic bone marrow transplantation (BMT), have resulted in the improvement of severe aplastic anemia (AA)1. However, in contrast to human leukocyte antigen-matched family donors-BMT, human leukocyte antigen-matched unrelated donors-BMT (MUD-BMT) continue to face life-threatening complications. Thus, it is essential to reduce these lethal complications and develop less-toxic preparative regimens for BMT from MUD1. Among the conditioning regimens, anti-thymocyte globulin (ATG) administration is an essential component of the preparative regimen that reduces the development of graft-versus-host disease (GVHD), although an excess dose of ATG increases graft failure, infection, and lymphoproliferative disorders1. However, the optimal dose and timing of administration of ATG also remain unclear in BMT from a MUD because of the absence of pharmacokinetics (PK) data of ATG in Japanese patients with AA2,4. Here, we report the PK of ATG in a patient with severe AA treated with BMT from a MUD.
Case Presentation

A 38-year-old woman with petechiae was referred to a regional hospital in July 2012. Laboratory results revealed pancytopenia, including a hemoglobin concentration of 4.6 g/dL, platelet count of 4 × 10^9/L, and white blood cell count of 2.87 × 10^9/L with 10.0% segmented neutrophils and 90% lymphocytes. A bone marrow biopsy revealed a fatty marrow. The chromosomal analysis displayed no abnormality.

Based on these findings, the patient was diagnosed with severe AA. Owing to the unavailability of human leukocyte antigen-matched family donors and the presence of paroxysmal nocturnal hemoglobinuria-type cells, the patient underwent a single course of IST consisting of ATG (Thymoglobulin®; Rabbit) 2.5 mg/kg x 2 days (day -7 and -6), Flu 30 mg/sqm x 4 days, CPA 25 mg/kg x 4 days and TBI 2 Gy.

However, the patient showed no response till 6 months after IST.

Following a discussion on the benefits and risks of a second round of IST and MUD-BMT, the patient underwent BMT from a genotypically full-matched human leukocyte antigen MUD following a less-toxic preparative regimen. According to previous reports from Japan, we administered a fludarabine (Flu)-based reduced-dose cyclophosphamide (CPA) conditioning regimen, consisting of ATG (2.5 mg/kg, on days -7 to -6), Flu (30 mg/sqm, on days -5 to -2), CPA (25 mg/kg, on days -5 to -2), and total body irradiation (TBI) (2 Gy, on day -1). Following the transfusion of bone marrow cells (3.9 × 10^8 cells/kg) from a male MUD, short-term administration of methotrexate (300 μg/day) administration and tacrolimus.
was initiated as prophylaxis for acute GVHD. Neutrophil ($0.5 \times 10^9/L$) and platelet ($50 \times 10^9/L$) engraftment were achieved on days 15 and 21, respectively. Notably, EBV reactivation and GVHD did not develop.

To analyze the serum concentrations of total rabbit ATG, we retrospectively estimated the area under the concentration-time curve (AUC) for ATG by measuring its blood concentrations before and after BMT (Figure 1B) using an enzyme-linked immunosorbent assay as described in a previous report. Additionally, the AUC

| Previous reports | N | Hematological disease | conditioning | ATG | Total ATG Concentration at day 0 (μg/mL) | AUC (μg · day/mL) | Half-lives (T 1/2) of total ATG (day) |
|------------------|---|-----------------------|--------------|-----|----------------------------------------|-----------------|-------------------------------------|
| Yamane et al. (IJH 2011, ref 3) | 57-year-old | AML | TBI 12 Gy High dose cytarabine (2400 mg/sqm) | ATG (thymoglobulin): 1.25 mg/kg: day −4 − day −2 | 28.8 | n.d. | n.d. |
| Matsumoto et al. (JSCT 2019, ref 4) | 38 cases | Hematological malignancy (AML 23, NHL 9, ALL 4, MDS 1, MF 1) | Flu + Mel + TBI 3 Gy (± Ara C) | ATG (thymoglobulin): 1.25 mg/kg: day −2 − day −1 | 27.5±8.7 | 528±33.2 | 24.3±22.7 |
| Our case | 38-year-old | Aplastic anemia | Flu (30 mg/sqm) × 4 + half-CPA (25 mg/kg) × 4 + TBI 2 Gy | ATG (thymoglobulin): 2.5 mg/kg: day −7 − day −6 | 21.8 | 464 | 12.4 |

Table 1B. Reports regarding aplastic anemia treated with a fludarabine (Flu)-based, reduced-cyclophosphamide (CPA) and ATG-inclusive regimen from Japan

| Previous reports | N | Conditioning | Engraft-ment | Acute GVHD | Chronic GVHD | EBV reactivation | OS |
|------------------|---|--------------|--------------|------------|-------------|-----------------|----|
| Kohashi et al. (IJH 2015, ref 5) | 6 (related 3, Unrelated 3) | Flu (30 mg/sqm) × 4 + half-CPA (100 mg/kg) | ATG (thymoglobulin): 2.5 mg/kg: day −4 − day −3 | 6/6 | 1/6 | — | 6/6 |
| Ashizawa et al. (IJH 2014, ref 6) | 4 (related donors: 4) | Flu (30 mg/sqm) × 4 + half-CPA (25 mg/kg) × 4 | ATG (zetbulin): 5 mg/kg: day −7 − day −3 | 4/4 | 2/4 | 1/4 | n.d. | 4/4 |
| | 3 (related 1, Unrelated 2) | | ATG (thymoglobulin): 2.5 mg/kg: day −5 − day −2 | 2/3 | 2/3 | 1/3 | n.d. | 1/3 |
| | 6 (related 3, Unrelated 3) | | ATG (thymoglobulin): 2.5 mg/kg: day −4 − day −3 | 6/6 | 3/6 | 6/6 | n.d. | 5/6 |
| Kako et al. (Am J Hematol 2019, ref 7) | 27 (related 16, Unrelated 11) | Flu (30 mg/sqm) × 4 + half-CPA (100 mg/kg) | ATG (thymoglobulin): 2.5 mg/kg: day −4 − day −3 | Median 19 days | Severe acute GVHD- 37.7% | Highly activation- 96.3% (=26/27) |
| Terasako et al. (Hematology 2010, ref 8) | 7 (related 6, Unrelated 1) | Flu (30 mg/sqm) × 4 + CPA (100 mg/kg) | ATG (zetbulin): 5 mg/kg: day −7 − day −3 | 7 | 2/7 | 4/7 | — | 6/7 |
| Our case | 38-year-old (unrelated donor) | Flu (30 mg/sqm) × 4 + half-CPA (25 mg/kg) × 4 + TBI 2 Gy | ATG (thymoglobulin): 2.5 mg/kg: day −7 − day −6 | Day 15 | — | — | 6 years |
and elimination half-life were calculated from the blood concentration data using a non-compartmental analysis with the PK analysis software, Phoenix® WinNonlin® 7.0 (Certara LP, Princeton, NJ, USA). According to the PK of ATG, the concentration of ATG on day 0 and the AUC for ATG after BMT were 21.8 μg/mL and 464 μg · day/mL, respectively. The half-life of total ATG was 12.4 days (Figure 1B). To date, the patient has been disease-free for 6 years.

Discussion

Here, we present the first report that analyzed the PK of ATG in AA treated with BMT from MUD (Table 1A). We safely performed the less-toxic Flu-based, reduced-dose CPA regimen containing a low dose of ATG and a low-dose TBI (Table 1B). In comparison to previous reports, ATG was administered earlier than that recommended in the conventional schedules to avoid excessive donor T-cell depletion. Furthermore, a low dose of TBI was added to avoid graft failure in BMT from MUD.

Regarding the PK of ATG in patients with allogeneic hematopoietic stem cell transplantation (allo-HSCT), it is currently unclear whether the recommended optimal dosage of ATG (4.5-7.5 mg/kg) in the Western population treated with allo-HSCT could be the optimal dose of ATG for the East Asian population, including the Japanese population that harbors different genetic backgrounds and a lower incidence of GVHD. Thus, the PK monitoring of ATG may be essential and useful to determine the optimal dosage of ATG in Japanese patients. In PK of ATG-related reports from Western countries, Rembarger M et al. reported that patients with total rabbit ATG serum concentrations >70 μg/mL on day 0 had a lower risk of developing severe acute GVHD than patients with concentrations <70 μg/mL (11% vs 48%) who were treated with allo-HSCT from a MUD. In a Japanese report of PK of ATG in allo-HSCT (Table 1A), Matsumoto et al. reported the PK of ATG as the total ATG concentration on day 0 (27.5 ± 8.7 μg/mL) in 38 patients with hematological malignancy treated with allo-HSCT. Although we cannot directly compare the PK of ATG with that reported previously owing to the differences in doses and timings of ATG, different underlying diseases, and the complexity and instability of the elimination kinetics of ATG among individual patients, our findings of ATG concentration on day 0 are almost consistent with the ATG concentration on day 0 as indicated by Matsumoto et al. Our case and previous reports may suggest that the ATG concentration on day 0 in patients in Japan may tend to be lower than that on day 0 in patients in Western countries. Further accumulations of the PK of ATG may reveal the optimal ATG concentration on day 0 and the optimal dose of ATG in Japanese patients with AA after BMT.

In conclusion, we present the first report that analyzed the PK of ATG in a patient with AA treated with BMT from a MUD. These findings might be helpful to determine ATG dosages in such patients receiving similar transplantations.

Acknowledgments

We are grateful to Mr. Nakamae for his valuable and insightful suggestions on the case.

Author Contributions

NK, KM and AT have contributed equally to this manuscript.

Conflicts of Interest

The authors declare no conflict of interest. Disclosure forms provided by the authors are available here.

References

1. Arai T, Nakao S, Kojima S, Hama A, Ohashi H, Kohara A, et al. Diagnostic and therapeutic guide for aplastic anemia in 2018.1-28. [Accessed August 4, 2020]

2. Park SS, Kwak DH, Jeon YW, Yoon JH, Lee SE, Cho BS, et al. Beneficial role of low-dose anti-thymocyte globulin in unrelated stem cell transplantation for adult patients with acquired severe aplastic anemia: reduction of graft-versus-host disease and improvement of graft-versus-host disease-free, failure-free survival rate. Biol Blood Marrow Transplant. 2017; 23: 1498-1508.

3. Yamane A, Mori T, Kato J, Ono Y, Okamoto S. Discrepancy in the kinetics of total and active antithymocyte globulin blood concentrations in recipients of allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2011; 93: 406-7.

4. Matsumoto K, Kaida K, Fukunaga K, Ikegame K, Ogawa K, Morita K. The Pharmacokinetics of anti-human thymocyte rabbit immunoglobulin in Japanese patients with hematopoietic stem cell transplantation. 41st annual meeting of the Japan Society for Hematopoietic Cell Transplantation: abstract, 2019, March 8th.

5. Kohashi S, Mori T, Hashida R, Kato J, Saburi M, Kikuchi T, et al. A combination of fludarabine, half-dose cyclo-
phosphamide, and anti-thymocyte globulin is an effective conditioning regimen before allogeneic stem cell transplantation for aplastic anemia. Int J Hematol. 2014; 99: 311-7.

7. Kako S, Kanda Y, Onizuka M, Aotsuka N, Usuki K, Tachibana T, et al. Kanto Study Group for Cell Therapy (KSGCT). Allogeneic hematopoietic stem cell transplantation for aplastic anemia with pre-transplant conditioning using fludarabine, reduced-dose cyclophosphamide, and low-dose thymoglobulin: A KSGCT prospective study. Am J Hematol. 2020; 95: 251-7.

8. Terasako K, Sato K, Sato M, Kimura S, Nakasone H, Okuda S, et al. The effect of different ATG preparations on immune recovery after allogeneic hematopoietic stem cell transplantation for severe aplastic anemia. Hematology. 2010; 15: 165-9.

9. Remberger M, Sundberg B. Rabbit-immunoglobulin G levels in patients receiving thymoglobulin as part of conditioning before unrelated donor stem cell transplantation. Haematologica. 2005; 90: 931-8.

10. McCune JS, Bemer MJ, Long-Boyle J. Pharmacokinetics, pharmacodynamics, and pharmacogenomics of immunosuppressants in allogeneic hematopoietic cell transplantation: Part II. Clin Pharmacokinet. 2016; 55: 551-93.

https://doi.org/10.31547/bct-2020-012
Copyright © 2021 APBMT. All Rights Reserved.